1. Home
  2. NATH vs TRDA Comparison

NATH vs TRDA Comparison

Compare NATH & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

HOLD

Current Price

$101.28

Market Cap

412.2M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$13.92

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATH
TRDA
Founded
1916
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
412.2M
481.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
NATH
TRDA
Price
$101.28
$13.92
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
14.8K
166.9K
Earning Date
02-05-2026
05-07-2026
Dividend Yield
1.97%
N/A
EPS Growth
22.29
N/A
EPS
4.17
N/A
Revenue
$104,201,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
$24.39
N/A
Revenue Growth
7.81
N/A
52 Week Low
$88.67
$4.93
52 Week High
$118.32
$14.36

Technical Indicators

Market Signals
Indicator
NATH
TRDA
Relative Strength Index (RSI) 56.47 60.17
Support Level $100.25 $10.84
Resistance Level $101.49 $13.99
Average True Range (ATR) 0.36 0.75
MACD 0.06 0.13
Stochastic Oscillator 43.90 87.63

Price Performance

Historical Comparison
NATH
TRDA

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: